These studies also showed that losartan, an angiotensin II receptor antagonist used in the treatment of hypertension, can block in vitro CCL2- and OS cell–elicited monocyte recruitment through noncompetitive inhibition of CCL2-induced ERK1/2 activation, independent of angiotensin II receptor signaling. Here, CCL2 is linked to Hypertension.